Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease
- PMID: 15149774
- DOI: 10.1016/j.vaccine.2003.11.047
Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease
Abstract
Serogroup A Neisseria meningitidis organisms of the subgroup III have caused epidemics of meningitis in sub-Saharan Africa since their introduction into the continent in 1987. The population structure of these bacteria is basically clonal, and these meningococci are strikingly similar in their major outer membrane antigens PorA and PorB. Protein-based vaccines might be an alternative to prevent epidemics caused by these meningococci; thus, we developed an outer membrane vesicle (OMV) vaccine from a serogroup A meningococcal strain of subgroup III. The serogroup A OMV vaccine was highly immunogenic in mice and elicited significant bactericidal activity towards several other serogroup A meningococci of subgroup III. The IgG antibodies generated were in immunoblot shown to be mainly directed towards the PorA outer membrane protein. The results presented demonstrate the potential of an OMV vaccine as an optional strategy to protect against meningococcal disease caused by serogroup A in Africa.
Similar articles
-
Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.Vaccine. 2005 May 31;23(29):3762-74. doi: 10.1016/j.vaccine.2005.02.021. Epub 2005 Mar 14. Vaccine. 2005. PMID: 15893613
-
An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt.Scand J Immunol. 2012 Aug;76(2):99-107. doi: 10.1111/j.1365-3083.2012.02709.x. Scand J Immunol. 2012. PMID: 22537024
-
Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.Vaccine. 2013 Dec 9;31(51):6097-106. doi: 10.1016/j.vaccine.2013.09.044. Epub 2013 Oct 10. Vaccine. 2013. PMID: 24120679
-
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.Vaccine. 2009 Jun 24;27 Suppl 2:B3-12. doi: 10.1016/j.vaccine.2009.04.071. Epub 2009 May 28. Vaccine. 2009. PMID: 19481313 Review.
-
Challenges and progress in the development of a serogroup B meningococcal vaccine.Expert Rev Vaccines. 2009 Jun;8(6):729-45. doi: 10.1586/erv.09.30. Expert Rev Vaccines. 2009. PMID: 19485754 Review.
Cited by
-
Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.Appl Microbiol Biotechnol. 2024 Feb 24;108(1):232. doi: 10.1007/s00253-024-13033-5. Appl Microbiol Biotechnol. 2024. PMID: 38396192 Free PMC article. Review.
-
Naturally produced outer membrane vesicles from Pseudomonas aeruginosa elicit a potent innate immune response via combined sensing of both lipopolysaccharide and protein components.Infect Immun. 2010 Sep;78(9):3822-31. doi: 10.1128/IAI.00433-10. Epub 2010 Jul 6. Infect Immun. 2010. PMID: 20605984 Free PMC article.
-
Expression of the iron-activated nspA and secY genes in Neisseria meningitidis group B by Fur-dependent and -independent mechanisms.J Bacteriol. 2007 Jan;189(2):663-9. doi: 10.1128/JB.01638-06. Epub 2006 Nov 3. J Bacteriol. 2007. PMID: 17085550 Free PMC article.
-
Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.PLoS One. 2012;7(12):e51045. doi: 10.1371/journal.pone.0051045. Epub 2012 Dec 12. PLoS One. 2012. PMID: 23251421 Free PMC article.
-
A homopolymeric adenosine tract in the promoter region of nspA influences factor H-mediated serum resistance in Neisseria meningitidis.Sci Rep. 2019 Feb 25;9(1):2736. doi: 10.1038/s41598-019-39231-0. Sci Rep. 2019. PMID: 30804422 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources